New options on the horizon for nononcogene addicted non-small-cell lung cancer

被引：2
作者：
Paglialunga, Luca [1 ]
Ricciardi, Serena [2 ]
D'Arcangelo, Manolo [3 ]
机构：
[1] AOU Careggi, Dept Med Oncol, Florence, Italy
[2] San Camillo Forlanini Hosp, Pneumol Oncol Unit, Rome, Italy
[3] AUSL Romagna, Dept Hematol Oncol, Ravenna, Italy
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 13期
关键词：
immune checkpoint inhibitors; NSCLC; therapeutic algorithm; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; OPEN-LABEL; PHASE-III; STAGE IV; 1ST-LINE TREATMENT; DOCETAXEL; NIVOLUMAB; PLACEBO; CHEMOTHERAPY;
D O I：
10.2217/fon-2018-0096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The treatment of non-small-cell lung cancer (NSCLC) has historically been based on platinum doublets- and taxan-based chemotherapy in the first- and second-line therapy, respectively. Although new agents have emerged for patients with driver mutations, treatment options for nononcogene addicted NSCLC have not changed for years. However, the last 5 years have seen the approval and introduction of new biological agents, such as immune checkpoint inhibitors and antiangiogenic drugs. The aim of this review is to give readers an update on the news in the treatment of nononcogene addicted NSCLC. As more and more therapeutic options are now available, we will delineate a potential therapeutic algorithm for the optimization of daily life treatment choice of NSCLC patients.
引用
收藏
页码：19 / 28
页数：10
相关论文
共 39 条
  • [1] [Anonymous], 2017, Cancer facts & fi gures 2017-special section: rare cancers in adults
  • [2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [3] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
  • [4] Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.
    Brahmer, Julie R.
    Rodriguez-Abreu, Delvys
    Robinson, Andrew George
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Leiby, Melanie A.
    McLean, Jessica
    Shentu, Yue
    Rangwala, Reshma A.
    Reck, Martin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
    Cappuzzo, Federico
    Ciuleanu, Tudor
    Stelmakh, Lilia
    Cicenas, Saulius
    Szczesna, Aleksandra
    Juhasz, Erzsebet
    Esteban, Emilio
    Molinier, Olivier
    Brugger, Wolfram
    Melezinek, Ivan
    Klingelschmitt, Gaelle
    Klughammer, Barbara
    Giaccone, Giuseppe
    [J]. LANCET ONCOLOGY, 2010, 11 (06) : 521 - 529
  • [6] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
    Carbone, D. P.
    Reck, M.
    Paz-Ares, L.
    Creelan, B.
    Horn, L.
    Steins, M.
    Felip, E.
    van den Heuvel, M. M.
    Ciuleanu, T. -E.
    Badin, F.
    Ready, N.
    Hiltermann, T. J. N.
    Nair, S.
    Juergens, R.
    Peters, S.
    Minenza, E.
    Wrangle, J. M.
    Rodriguez-Abreu, D.
    Borghaei, H.
    Blumenschein, G. R.
    Villaruz, L. C.
    Havel, L.
    Krejci, J.
    Corral Jaime, J.
    Chang, H.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Chen, A. C.
    Socinski, M. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) : 2415 - 2426
  • [7] Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study)
    Cicenas, Saulius
    Geater, Sarayut Lucien
    Petrov, Petar
    Hotko, Yevgeniy
    Hooper, Gregory
    Xia, Fan
    Mudie, Nadejda
    Wu, Yi-Long
    [J]. LUNG CANCER, 2016, 102 : 30 - 37
  • [8] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
    Ciuleanu, Tudor
    Brodowicz, Thomas
    Zielinski, Christoph
    Kim, Joo Hang
    Krzakowski, Maciej
    Laack, Eckart
    Wu, Yi-Long
    Bover, Isabel
    Begbie, Stephen
    Tzekova, Valentina
    Cucevic, Branka
    Pereira, Jose Rodrigues
    Yang, Sung Hyun
    Madhavan, Jayaprakash
    Sugarman, Katherine P.
    Peterson, Patrick
    John, William J.
    Krejcy, Kurt
    Belani, Chandra P.
    [J]. LANCET, 2009, 374 (9699) : 1432 - 1440
  • [9] Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network metaanalysis
    Crequit, Perrine
    Chaimani, Anna
    Yavchitz, Amelie
    Attiche, Nassima
    Cadranel, Jacques
    Trinquart, Ludovic
    Ravaud, Philippe
    [J]. BMC MEDICINE, 2017, 15
  • [10] Overall survival in non-small cell lung cancer-what is clinically meaningful?
    Fenchel, Klaus
    Sellmann, Ludger
    Dempke, Wolfram C. M.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 115 - 119
1234